Methadone maintenance treatment in Spain: The success of a harm reduction approach;El tratamiento de mantenimiento con metadona en España: El éxito de un enfoque dirigido a la reducción de daños

Bulletin of the World Health Organization

Volumn 91, Issue 2, 2013, Pages 136-141

  Torrens, Marta ^a   Fonseca, Francina ^a   Castillo, Claudio ^a   Domingo Salvany, Antonia ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; ILLICIT DRUG; METHADONE; NALOXONE; OPIATE;

DRUG; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MORBIDITY; MORTALITY; PUBLIC HEALTH; QUALITY OF LIFE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL DECISION MAKING; DISEASE TRANSMISSION; DRUG SCREENING; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HARM REDUCTION; HEALTH CENTER; HEALTH PROGRAM; HEALTH SERVICE; HEROIN DEPENDENCE; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LAW; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OPIOID AGONIST MAINTENANCE TREATMENT; PATIENT COUNSELING; POLICY; PRESCRIPTION; PRISON; PUBLIC HEALTH; QUALITY OF LIFE; REHABILITATION CARE; SPAIN; TREATMENT DURATION; URINALYSIS;

SPAIN;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84873300846     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.12.111054     Document Type: Article

References (18)

1. Sánchez-Niubò A, Fortiana J, Barrio G, Suelves JM, Correa JF, Domingo-Salvany A. Problematic heroin use incidence trends in Spain. Addiction 2009;104:248-55. doi:10.1111/j.1360-0443.2008.02451.x
2. De la Fuente L, Bravo MJ, Barrio G, Parras F, Suárez M, Rodés A et al. Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin Infect Dis 2003;37:S410-5. doi:10.1086/377562
3. Camí J, de Torres S, San L. Guidelines and criteria for the admission of heroin dependence in the general hospital. Med Clin (Barc) 1984;82:327-31.
4. Torrens M. Spain. In: Casselman J, Meuwissen J, Opdebeeck A, editors.The legal aspects of substitution treatment: an insight into nine EU countries. Belgium: European Monitoring Centre for Drugs and Drug Addiction; 2003. pp. 61-9.
5. Barrio G, Bravo MJ, Brugal MT, Díez M, Regidor E, Belza MJ et al.; Itinere Working Group. Harm reduction interventions for drug injectors or heroin users in Spain: expanding coverage as the storm abates. Addiction 2012;107:1111-22. doi:10.1111/j.1360-0443.2011.03759.x
6. García-Alonso F, Gutierrez M, San L, Bedate J, Forteza-Rei J, Rodríguez-Artalejo F et al.; Spanish Study Group in Drug Addiction. A multicentre study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 1989;23:117-21. doi:10.1016/0376-8716(89)90016-1
7. Torrens M, Camí J. The effects of HIV infection on the development of methadone maintenance treatment in Spain. Addiction 1994;89:1707-8.
8. Domingo-Salvany A, Pérez K, Torrens M, Bravo MJ, Antó JM, Alonso J. Methadone treatment in Spain, 1994. Drug Alcohol Depend 1999;56:61-6. doi:10.1016/S0376-8716(99)00011-3
9. Domingo-Salvany A. Los tratamientos de mantenimiento con metadona en España: análisis de los centros activos en 1997. In: VI Encuentro Nacional sobre Drogodependencias y su Enfoque Comunitario,3-5 November 1999, Cadiz, Spain. Cadiz: Centro Provincial de Drogodependencias de Cádiz; 1999. [Spanish].
10. Plan Nacional sobre Drogas. Memoria 1996. Madrid: Delegación del Gobierno para el Plan Nacional Sobre Drogas, Ministerio del Interior; 1996. [Spanish].
11. Plan Nacional sobre Drogas. Memoria 2009. Madrid: Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio del Interior; 2009. [Spanish].
12. Torrens M, Castillo C, Pérez-Solá V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend 1996;41:55-9. doi:10.1016/0376-8716(96)01230-6
13. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, García de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005;100:981-9. doi:10.1111/j.1360-0443.2005.01089.x
14. Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L. Methadone and quality of life. Lancet 1999;353:1101. doi:10.1016/S0140-6736(05)76462-X
15. World Health Organization/United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS. WHO, UNODC, UNAIDS Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: WHO, UNODC, UNAIDS; 2009. Available from: http://www.unodc.org/documents/hiv-aids/idu_target_setting_guide.pdf [accessed 8 December 2012].
16. European Monitoring Centre for Drugs and Drug Addiction [Internet]. Data: statistical bulletin 2011. Lisbon: EMCDDA; 2011. Available from: http://www.emcdda.europa.eu/stats11 [accessed 8 December 2012].
17. European Monitoring Centre for Drugs and Drug Addiction. Annual report 2011: the state of the drugs problems in Europe. Lisbon: EMCDDA; 2011. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf [accessed 8 December 2012].
18. de Sanidad M, Sociales e Igualdad S. Plan Nacional sobre Drogas [Internet]. Consumo, percepciones y opiniones de la población ante las drogas.1.1 Encuesta Domiciliaria sobre Alcohol y Drogas en España (EDADES), 1959-1999. Madrid: MSSSI; 2009. Available from: http://www.pnsd.msc.es/Categoria2/observa/pdf/EDADES_2009.pdf [accessed 8 December 2012]. [Spanish].